Chemotherapy-related Cognitive Impairment
13
1
2
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.7%
1 terminated out of 13 trials
83.3%
-3.2% vs benchmark
23%
3 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
Evaluation of Cognitive Education Activities in Breast Cancer Patients Receiving Chemotherapy
nCCR for Chemotherapy Related Cognitive Impairment Randomized Study
Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment
Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.
Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment
Electroacupuncture for Chemotherapy-Related Cognitive Impairment
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study
Biomarkers for Chemotherapy Associated Neurotoxicity
Neuroplasticity-Based Cognitive Remediation for Chemotherapy-Related Cognitive Impairment
Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study